Company Active LTD

Company profile

Willingsford Limited

Passive Immunotherapy treatment for wounds and wounds associated with dermatological conditions - Willingsford Healthcare

New disruptive technology for treating wound infections. Approved for all wound types. Version for wounds and pressure ulcers in spinal cord injury (SCI)

CRN
07462271
Founded
2010
Age
15

Overview

Legal name
WILLINGSFORD LIMITED
Region
South East England
Registered address
NEW FOREST ENTERPRISE CENTRE CHAPEL LANE
TOTTON
SOUTHAMPTON
HAMPSHIRE
SO40 9LA
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

5 events
21 Dec
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

07 Dec
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

07 Dec
2010

Incorporated

Inception

Company registered at Companies House

Public funding

4 awards
First funded
2012
Funded years
2012, 2017, 2019, 2020
Age at first award
1 years

Projects

2020 Small Business Research Initiative Lead participant

Integrated use of telemedicine and AI in wound treatment - contributing to public sector financial and environmental sustainability and resilience during pandemics.

1 Oct 2020 to 31 Dec 2020

Awarded
£51,119
Total cost £51,119

Cost of healthcare in the UK and world-wide continues to place an increasing burden on public finances, e.g. the 2019 NHS budget was £134 billion. There are annually 2.3 million wounds in the UK, but treatment times are long and 39% remain unhealed because existing treatments are ineffective. Wounds therefore annually cost the NHS £17.3 bn and require 278...

2019 CR&D Bilateral Lead participant

RCT protocol development to evaluate MPPT in venous leg ulcers

1 May 2019 to 30 Apr 2020

Awarded
£24,997
Total cost £49,994

"The main reason wounds and ulcers have difficulty or fail to heal is infection. For the past decade, it has been standard medical practice to use antimicrobials to treat wound infections, but several clinical studies have shown that they have minimal effects and NICE and the FDA no longer encourage their use. Furthermore, both antibiotics and antiseptics...

2017 Feasibility Studies Lead participant

Novel drying method for advanced materials

1 May 2017 to 30 Apr 2018

Awarded
£44,954
Total cost £99,895

Acapsil is a CE-marked novel first-in-class advanced biomaterial, which has demonstrated effects in wound care. Annually in the UK, 2.2 mill wounds require treatment causing direct costs to the NHS of £5.3 bn. Acapsil accelerates wound healing by 60% and reduces bed-days by 31% for hospital in-patients with acute and chronic wounds and ulcers. Estimates i...

2012 GRD Development of Prototype Lead participant

SertaSil - novel medical device for advanced wound care

1 Jan 2012 to 30 Sep 2015

Awarded
£194,673
Total cost £341,053

The NHS spends each year over £3bn on wound care and at any one time in the UK there are over 600,000 wounds that cannot heal. In the EU there are over 12 mil wounds and burns annually requiring extended treatment or hospitalisation. However, current treatments have limited effects and there is an urgent need for improved wound care products. SertaSil is ...

Product types

CR&D Bilateral Feasibility Studies GRD Development of Prototype Small Business Research Initiative